Scarica l'app Stockscreener
28.31
2.71%
0.7898
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$27.52
Aprire:
$27.93
Volume 24 ore:
1.63M
Relative Volume:
0.28
Capitalizzazione di mercato:
$20.26B
Reddito:
$13.31M
Utile/perdita netta:
$-1.01B
Rapporto P/E:
-24.23
EPS:
-1.1685
Flusso di cassa netto:
$-766.86M
1 W Prestazione:
+0.44%
1M Prestazione:
+7.02%
6M Prestazione:
+44.35%
1 anno Prestazione:
+143.24%
Intervallo 1D:
$27.89
$28.55
Intervallo di 1 settimana:
$27.06
$28.58
Portata 52W:
$10.58
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.30 | 19.88B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
428.28 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
703.50 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.44 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
315.59 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
296.31 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Outperform |
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake - Insider Monkey
Roivant Sciences: Moderna Settlement, Brepocitinib Support A Long-Term Buy (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 30% Upside in Healthcare Biotech - DirectorsTalk Interviews
Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential - Insider Monkey
Roivant Sciences Ltd. $ROIV Stake Cut by Impax Asset Management Group plc - MarketBeat
Roivant Sciences (ROIV) Valuation Check After Recent Share Price Volatility - simplywall.st
M&T Bank Corp Takes Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Montes Archimedes Acquisition (ROIV) upgraded to buy: Here's what you should know - MSN
Citigroup Maintains Roivant Sciences (ROIV) Buy Recommendation - MSN
Price-Driven Insight from (ROIV) for Rule-Based Strategy - Stock Traders Daily
Roivant Sciences Insider Sold Shares Worth $5,918,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Roivant Sciences(ROIV.US) Officer Sells US$5.92 Million in Common Stock - Moomoo
Roivant (NASDAQ: ROIV) president exercises 200K options, sells shares - Stock Titan
Roivant Sciences (ROIV) CFO awarded 60,644 RSUs and 84,026 stock options - Stock Titan
Roivant Sciences (ROIV) grants CAO new RSUs and stock options - Stock Titan
Roivant Sciences (ROIV) director gets share award, settles taxes in stock - Stock Titan
Roivant Sciences (ROIV) director gets fully vested 670-share award - Stock Titan
Roivant Sciences (ROIV) director gets share grant with tax netting - Stock Titan
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Roivant Sciences Insider Sold Shares Worth $8,449,810, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (ROIV) CEO sells 289,774 shares around $29 - Stock Titan
Roivant (ROIV) Stock Insider Ownership (Smart Money Outflows) 2026-04-20Shared Trade Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat - MSN
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $35 - Moomoo
ROIV Maintained by Piper Sandler -- Price Target Raised to $40 - GuruFocus
Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 8.45 Million in Common Stocks - Moomoo
Matthew Gline sells $8.44M in ROIV stock (ROIV) — insider Form 144 filing - Stock Titan
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Piper Sandler Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $40 - Moomoo
Consolidated Portfolio Review Corp Acquires Shares of 276,530 Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure - Insider Monkey
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
Goldman Sachs Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
10 Must-Buy US Stocks to Buy Right Now - Insider Monkey
A Look At Roivant Sciences (ROIV) Valuation As Analyst Upgrades And Brepocitinib Progress Lift Sentiment - simplywall.st
(ROIV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences: How Its Unique Deal Structure With Pfizer Could Shape Long-Term Value! - Smartkarma
Is Brepocitinib’s LPP Trial And Mixed Batoclimab Data Altering The Investment Case For Roivant Sciences (ROIV)? - simplywall.st
Insider Sell Alert: Jennifer Humes Sells Shares of Roivant Scien - GuruFocus
Montes Archimedes Acquisition (ROIV) Raised to Buy: Key Information You Need - Bitget
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CAO Sells 13,538 Shares of Stock - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Roivant Sciences (ROIV), Boston Scientific (BSX) - The Globe and Mail
What happens to Roivant (ROIV) Stock after earnings | Price at $28.44, Up 0.96%Stock Analysis - Xã Thanh Hà
Roivant Sciences Ltd. (ROIV) Stock forecasts - Yahoo Finance UK
Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Apr 20 '26 |
Sale |
29.59 |
200,000 |
5,918,000 |
1,647,546 |
| Gline Matthew | CEO |
Apr 16 '26 |
Sale |
29.16 |
289,774 |
8,449,810 |
16,736,116 |
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):